Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

ABSTRACT:

Purpose

To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.

Methods

Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m² once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m² once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m² over 3 hours day 1, IP cisplatin 75 mg/m² day 2, and IP paclitaxel 60 mg/m² day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22.

Results

A total of 1,560

SUBMITTER: Walker JL 

PROVIDER: S-EPMC6544459 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature